Abstract

An impediment to curing HIV-1 infection is the persistence of latently infected cells in ART-treated people living with HIV (PLWH). A key strategy for curing HIV-1 infection is to activate transcription and translation of latent virus using latency reversing agents (LRAs) and eliminate cells harboring reactivated virus via viral cytopathic effect or immune clearance. In this review, we provide an overview of available LRAs and their use in clinical trials. Furthermore, we describe recent data suggesting that CD8+ T cells promote HIV-1 latency in the context of ART, even in the presence of LRAs, which might at least partially explain the clinical inefficiency of previous “shock and kill” trials. Here, we propose a novel cure strategy called “unlock, shock, disarm, and kill”. The general premise of this strategy is to shut down the pro-latency function(s) of CD8+ T cells, use LRAs to reverse HIV-1 latency, counteract anti-apoptotic molecules, and engage natural killer (NK) cells to mediate the killing of cells harboring reactivated latent HIV-1.

Highlights

  • An impediment to curing HIV-1 infection is the persistence of latently infected cells in antiretroviral therapy (ART)-treated people living with HIV (PLWH)

  • PLWH revealed that none of the in vitro models were able to truly recapitulate the ex vivo activity of latency reversing agents (LRAs) on latently infected cells isolated from HIV-1-infected individuals on ART [64]

  • LRA activity have been characterized [9]. These agents reactivate latent HIV1 in in vitro assays, their ability to reactivate latent virus following in vivo administration is modest, and they do not facilitate reductions in the size of the reservoir in PLWH [11,12,13,14,15,16,17,18,19,20,21]

Read more

Summary

The LRA Landscape

Various classes of HIV-1 LRAs have been identified for their ability to induce reactiVarious classes of HIV-1 LRAs have been identified for their ability to induce reactivavation of latent HIV-1. PLWH revealed that none of the in vitro models were able to truly recapitulate the ex vivo activity of LRAs on latently infected cells isolated from HIV-1-infected individuals on ART [64]. It is clear, from ex vivo experiments, that treatment with a combination of LRAs may be required to achieve an adequate amount of virus reactivation to facilitate efforts to diminish the size of the latent reservoir [65].

Clinical Trials of the “Shock and Kill” Approach
Viralrhesus dynamics following
Outstanding Questions about the Role of NK Cells in Promoting Viral Latency
A Novel Multi-Pronged “Shock and Kill” HIV-1 Cure Strategy
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.